Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.73 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.70 |
| ▸ | MAPT | P10636 | 4/20 | 0.62 |
| ▸ | NPC1 | O15118 | 3/20 | 0.62 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.62 |
| ▸ | HPGD | P15428 | 2/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.62 |
| ▸ | LMNA | P02545 | 2/20 | 0.62 |
| ▸ | S1PR1 | P21453 | 9/20 | 0.60 |
| ▸ | S1PR3 | Q99500 | 5/20 | 0.60 |
| ▸ | RAB9A | P51151 | 2/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | TSHR | P16473 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.54 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20116413 | 0.88 | SMN1; SMN2 (0.65) | SMN1; SMN2MAPK1MAPTNPC1HSD17B10 | |
| SCHEMBL20116544 | 0.86 | SMN1; SMN2 (0.73) | SMN1; SMN2MAPK1MAPTNPC1HSD17B10 | |
| SCHEMBL19766693 | 0.78 | S1PR1 (0.91) | SMN1; SMN2MAPTNPC1HSD17B10ALDH1A1 | |
| SCHEMBL15662740 | 0.76 | SMN1; SMN2 (0.74) | SMN1; SMN2MAPK1MAPTNPC1HSD17B10 | |
| SCHEMBL22343934 | 0.76 | SMN1; SMN2 (0.60) | SMN1; SMN2MAPK1MAPTNPC1HSD17B10 | |
| SCHEMBL20169182 | 0.76 | S1PR1 (0.89) | SMN1; SMN2MAPK1MAPTNPC1HSD17B10 | |
| SCHEMBL27834106 | 0.76 | SMN1; SMN2 (0.77) | SMN1; SMN2MAPTNPC1HSD17B10ALDH1A1 | |
| SCHEMBL20116669 | 0.76 | SMN1; SMN2 (0.59) | SMN1; SMN2MAPK1MAPTNPC1HSD17B10 | |
| SCHEMBL20116375 | 0.76 | TLR9 (0.66) | SMN1; SMN2MAPK1MAPTNPC1HSD17B10 | |
| SCHEMBL1413267 | 0.75 | S1PR1 (1.00) | SMN1; SMN2MAPTNPC1HSD17B10ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12275723-B2 | Compounds and uses thereof | JANSSEN PHARMACEUTICA NV (BE) | 2025-04-15 | — | — | US | disclosed |
| US-20240400546-A1 | COMPOUNDS AND USES THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2024-12-05 | — | — | US | disclosed |
| US-20240300938-A1 | COMPOUNDS AND USES THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2024-09-12 | — | — | US | disclosed |
| US-11970486-B2 | Compounds and uses thereof | JANSSEN PHARMACEUTICA NV (BE) | 2024-04-30 | — | — | US | disclosed |
| US-20240124435-A1 | COMPOUNDS AND USES THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2024-04-18 | — | — | US | disclosed |
| CN-117777121-A | Compounds and uses thereof | 詹森药业有限公司 | 2024-03-29 | — | — | CN | disclosed |
| US-11873298-B2 | Compounds and uses thereof | JANSSEN PHARMACEUTICA NV (BE) | 2024-01-16 | — | — | US | disclosed |
| US-11873298-B2 | Compounds and uses thereof | JANSSEN PHARMACEUTICA NV (BE) | 2024-01-16 | — | — | US | disclosed |
| US-11873298-B2 | Compounds and uses thereof | JANSSEN PHARMACEUTICA NV (BE) | 2024-01-16 | — | — | US | disclosed |
| CN-110099898-B | Compounds and uses thereof | 优曼尼蒂治疗公司 | 2023-07-25 | — | — | CN | disclosed |
| EP-3700934-A1 | COMPOUNDS AND USES THEREOF | Yumanity Therapeutics, Inc. (US) | 2020-09-02 | — | — | EP | disclosed |
| US-20200262828-A1 | COMPOUNDS AND USES THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2020-08-20 | — | — | US | disclosed |
| US-20200262828-A1 | COMPOUNDS AND USES THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2020-08-20 | — | — | US | disclosed |
| WO-2019209948-A9 | COMPOUNDS AND USES THEREOF | YUMANITY THERAPEUTICS, INC. (US) | 2020-01-02 | — | — | WO | disclosed |
| WO-2019209948-A9 | COMPOUNDS AND USES THEREOF | YUMANITY THERAPEUTICS, INC. (US) | 2020-01-02 | — | — | WO | disclosed |
| EP-3529245-A1 | COMPOUNDS AND USES THEREOF | Yumanity Therapeutics, Inc. (US) | 2019-08-28 | — | — | EP | disclosed |
| WO-2019018795-A1 | COMPOUNDS AND USES THEREOF | YUMANITY THERAPEUTICS (US) | 2019-01-24 | — | — | WO | disclosed |
| WO-2019018795-A1 | COMPOUNDS AND USES THEREOF | YUMANITY THERAPEUTICS (US) | 2019-01-24 | — | — | WO | disclosed |
| WO-2018081167-A1 | COMPOUNDS AND USES THEREOF | YUMANITY THERAPEUTICS (US) | 2018-05-03 | — | — | WO | disclosed |
| WO-2018081167-A1 | COMPOUNDS AND USES THEREOF | YUMANITY THERAPEUTICS (US) | 2018-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240124435-A1 | COMPOUNDS AND USES THEREOF | NLN, ACHE, CLN6 | SMN1; SMN2 13/4885MAPK1 4304/4885MAPT 22/4885 |
| US-20240300938-A1 | COMPOUNDS AND USES THEREOF | NLN, ACHE, CLN6 | SMN1; SMN2 13/4885MAPK1 4304/4885MAPT 22/4885 |
| US-11873298-B2 | Compounds and uses thereof | NLN, ACHE, CLN6 | SMN1; SMN2 13/4885MAPK1 4304/4885MAPT 22/4885 |
| US-20240400546-A1 | COMPOUNDS AND USES THEREOF | NLN, ACHE, CLN6 | SMN1; SMN2 13/4885MAPK1 4304/4885MAPT 22/4885 |
| US-12275723-B2 | Compounds and uses thereof | NLN, ACHE, CLN6 | SMN1; SMN2 13/4885MAPK1 4304/4885MAPT 22/4885 |
| US-20200262828-A1 | COMPOUNDS AND USES THEREOF | NLN, ACHE, CLN6 | SMN1; SMN2 13/4885MAPK1 4304/4885MAPT 22/4885 |
| US-11970486-B2 | Compounds and uses thereof | NLN, ACHE, CLN6 | SMN1; SMN2 13/4885MAPK1 4304/4885MAPT 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.